Douglas K Spracklin - JoVE Visualize

Showing results (11-20 of 21) with videos related to

Pageof 3

Sort By:

Clinical Pharmacology and Therapeutics|December 11, 2023

Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working GroupWenkui Li, Faye Vazvaei-Smith, Gordon Dear, et al.

Clinical Pharmacology and Therapeutics|November 29, 2023

Non-Labeled, Stable Labeled, or Radiolabelled Approaches for Provision of Intravenous Pharmacokinetics in Humans: A Discussion PieceGraeme C Young, Douglas K Spracklin, Alexander D James, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 12, 2024

Recommendations on the Use of Multiple Labels in Human Mass Balance StudiesFilip Cuyckens, Mette G Hvenegaard, Kenneth C Cassidy, et al.

Journal of Medicinal Chemistry|May 29, 2020

Late-Stage Lead Diversification Coupled with Quantitative Nuclear Magnetic Resonance Spectroscopy to Identify New Structure-Activity Relationship Vectors at Nanomole-Scale Synthesis: Application to Loratadine, a Human Histamine H<sub>1</sub> Receptor Inverse AgonistManjinder S Lall, Asser Bassyouni, James Bradow, et al.

Bioorganic & Medicinal Chemistry Letters|March 31, 2009

3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimizationAllen J Duplantier, Ivan Efremov, John Candler, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 2018

A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the "Metabolites in Safety Testing" Regulatory GuidanceSimone Schadt, Bojan Bister, Swapan K Chowdhury, et al.

Clinical Pharmacology and Therapeutics|June 23, 2022

Considerations for Human ADME Strategy and Design Paradigm Shift(s) - An Industry White PaperGraeme C Young, Douglas K Spracklin, Alexander D James, et al.

The Journal of Pharmacology and Experimental Therapeutics|August 22, 2006

Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139Thomas A Lanz, Michael J Karmilowicz, Kathleen M Wood, et al.

Journal of Medicinal Chemistry|January 2, 2010

Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition modelsChristopher J O'Donnell, Bruce N Rogers, Brian S Bronk, et al.

Journal of Medicinal Chemistry|September 21, 2011

Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764)Travis T Wager, Betty A Pettersen, Anne W Schmidt, et al.

Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:

Pageof 3

Clinical Pharmacology and Therapeutics|December 11, 2023

Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working GroupWenkui Li, Faye Vazvaei-Smith, Gordon Dear, et al.

Clinical Pharmacology and Therapeutics|November 29, 2023

Non-Labeled, Stable Labeled, or Radiolabelled Approaches for Provision of Intravenous Pharmacokinetics in Humans: A Discussion PieceGraeme C Young, Douglas K Spracklin, Alexander D James, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 12, 2024

Recommendations on the Use of Multiple Labels in Human Mass Balance StudiesFilip Cuyckens, Mette G Hvenegaard, Kenneth C Cassidy, et al.

Journal of Medicinal Chemistry|May 29, 2020

Late-Stage Lead Diversification Coupled with Quantitative Nuclear Magnetic Resonance Spectroscopy to Identify New Structure-Activity Relationship Vectors at Nanomole-Scale Synthesis: Application to Loratadine, a Human Histamine H<sub>1</sub> Receptor Inverse AgonistManjinder S Lall, Asser Bassyouni, James Bradow, et al.

Bioorganic & Medicinal Chemistry Letters|March 31, 2009

3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimizationAllen J Duplantier, Ivan Efremov, John Candler, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 2018

A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the "Metabolites in Safety Testing" Regulatory GuidanceSimone Schadt, Bojan Bister, Swapan K Chowdhury, et al.

Clinical Pharmacology and Therapeutics|June 23, 2022

Considerations for Human ADME Strategy and Design Paradigm Shift(s) - An Industry White PaperGraeme C Young, Douglas K Spracklin, Alexander D James, et al.

The Journal of Pharmacology and Experimental Therapeutics|August 22, 2006

Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139Thomas A Lanz, Michael J Karmilowicz, Kathleen M Wood, et al.

Journal of Medicinal Chemistry|January 2, 2010

Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition modelsChristopher J O'Donnell, Bruce N Rogers, Brian S Bronk, et al.

Journal of Medicinal Chemistry|September 21, 2011

Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764)Travis T Wager, Betty A Pettersen, Anne W Schmidt, et al.

Pageof 3